Eric Bell Mendoza, PSYD Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 852 E Danenberg Dr., El Centro, CA 92243 Phone: 760-352-2257 |
Dr. Alan Leavens, PHD Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 230 S 8th St, El Centro, CA 92243 Phone: 760-332-8131 |
Dr. Cornelius Cuza, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2695 S 4th St, El Centro, CA 92243 Phone: 760-482-4000 |
Dr. Louis Michael Blumberg, PH.D. Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 202 N 8th St, El Centro, CA 92243 Phone: 760-482-4087 |
Mrs. Frances A Terrazas, EDUCATION SPECIALIST Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 1744 Desert Gardens Dr, El Centro, CA 92243 Phone: 760-996-7706 |
Sudhakar Ravada, EDD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 202 N 8th St, El Centro, CA 92243 Phone: 442-265-1525 |
Dr. Mohamed Abdallah, PSY.D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 852 E Danenberg Dr., El Centro, CA 92243 Phone: 760-352-2257 |
News Archive
​Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes that patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations, but a poorer prognosis.
A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients.
Diets rich in certain plant-based foods are linked with the presence of gut microbes that are associated with a lower risk of developing conditions such as obesity, type 2 diabetes and cardiovascular disease, according to recent results from a large-scale international study that included researchers from King's College London, the Harvard T.H. Chan School of Public Health, Massachusetts General Hospital, the University of Trento, Italy, and health science start-up company ZOE.
Nature News reports on "the possibility of unintended public-health consequences" of pre-exposure prophylaxis (PrEP) for HIV and pharmaceutical company Gilead's plan to ask the FDA to evaluate its combination antiretroviral (ARV) drug Truvada for use in healthy people.
› Verified 9 days ago